Hypophosphatemic Rickets X-linked Dominant
📧 Sign up to get email alerts when something new happens for Hypophosphatemic Rickets X-linked Dominant.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-10EMA Authorised: Crysvita (burosumab) — Kyowa Kirin Holdings B.V.
EU authorization for Crysvita (burosumab) for familial hypophosphatemia, X-linked dominant hypophosphatemic rickets, and osteomalacia, grant…